6533b85afe1ef96bd12b9f9c

RESEARCH PRODUCT

Maintenance therapy with avelumab (MSB0010718C; anti-PD-L1) vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric cancer: The phase 3 JAVELIN Gastric 100 trial.

Markus MoehlerJulien TaiebJenny ZhangNarikazu BokuJean-marie CuillerotHuiling XiongJayne S. Gurtler

subject

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybiologybusiness.industryLocally advancedbiology.organism_classificationAvelumab03 medical and health sciences030104 developmental biology0302 clinical medicineImmune systemOncologyMaintenance therapyJavelin030220 oncology & carcinogenesisInternal medicinemedicineIn patientFirst line chemotherapyReceptorbusinessmedicine.drug

description

TPS4134Background: Programmed death-1 receptor ligand (PD-L1) is a key therapeutic target in the reactivation of the immune response against multiple cancers. Avelumab* is a fully human anti-PD-L1 ...

https://doi.org/10.1200/jco.2016.34.15_suppl.tps4134